Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

CONCERTA(R) now available for patients with ADHD ages 6 to 65

RARITAN, N.J., June 27 /PRNewswire/ -- ADHD is the most common emotional, cognitive and behavioral disorder treated in children(1), and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years(2). ADHD is thought to affect about eight million, or one in 20, adults in the United States(3), and research on the life span of the condition notes the disorder impairs academic, social and occupational functioning(1), and is associated with academic underachievement, conduct problems, underemployment, motor vehicle safety and difficulties with personal relationships(1).

Today, there's a new treatment option for the millions of adults in the United States with ADHD: Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD) announced the U.S. Food and Drug Administration (FDA) approved J&JPRD's Supplemental New Drug Application (sNDA) for CONCERTA(R) treatment of ADHD in adults ages 18 to 65. The doses approved for adults range from 18 to 72 mg daily.

Today's approval expands the CONCERTA(R) indication from children and adolescents into adults with ADHD, and offers these patients a patented once- daily formulation. Using its unique OROS(R) delivery system, the CONCERTA(R) formulation delivers an initial dose of medication when the tablet is ingested. Medication is then delivered into the bloodstream at a controlled rate throughout the day.

The CONCERTA(R) brand, which was the first 12-hour extended-release methylphenidate (MPH) treatment for ADHD, is the market leader for MPH treatment of children and adolescents with ADHD. CONCERTA(R) is marketed in the United States by McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

"What we've seen in the growing body of knowledge on adult ADHD suggests a challenging burden of impairme
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... N.J. , March 30, 2015  New Jersey ... innovation projects in the state of New ... next round of grant funding, announced James M. ... Jersey Health Foundation Research Grants program, an additional $500,000 ... each to fund early stage research projects that demonstrate ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... NGSX ), a biopharmaceutical company focused on developing ... results for its fourth quarter and year-end 2007 on ... conference call to review the results will begin at ... and will be hosted by Anthony DiTonno,President and Chief ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... and Special Meeting of Shareholders,being held at the ... at 4:30 p.m. ET., To participate via ...
... Md., March 18 Martek Biosciences,(Nasdaq: MATK ) ... with,life,sDHA(TM), its patented, vegetarian form of DHA omega-3 for ... bread with vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA ... in the Pacific Northwest, California, Arizona,and Nevada., "This ...
Cached Biology Technology:NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 2NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 3Vasogen to Webcast its Annual Meeting 2Vasogen to Webcast its Annual Meeting 3Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3
(Date:3/10/2015)... March 10, 2015  Continuing its 167-year history of ... Schlemmer introduces The Eye Scanning Password Authenticator , ... access to secure websites or sensitive data. ... at international borders, the device has a small camera ... of the iris, converting them into an encrypted ID ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... EUREKA project E! 4104 ECOPROMAT has developed a ... protection against the spread of contagious animal diseases such ... and food production. Soaked with disinfectant solution, the matting ... shoes and boots of personnel. As it is made ...
... imitated Mother Nature by developing, for the first ... the tiny, hair-like structures through which organisms derive ... the new material isn,t exactly like cilia, it ... researchers to control it and opening unlimited possibilities ...
... the little engine that could, the University of Nevada, ... is chugging along, dwarfed by the million-gallon tanks, pipes ... where, ultimately, the plant,s electrical power could be supplied ... "We are very pleased with the results of the ...
Cached Biology News:A biological solution to animal pandemics 2A biological solution to animal pandemics 3A biological solution to animal pandemics 4Cilia revolution 2University of Nevada, Reno demonstrates successful sludge-to-power research 2University of Nevada, Reno demonstrates successful sludge-to-power research 3
... double stranded RNA (dsRNA) has been shown ... group of organisms as well as insect ... the inhibition of protein expression by utilizing ... RNA (mRNA). Attempts to induce RNA interference ...
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
... double stranded RNA (dsRNA) has been shown ... group of organisms as well as insect ... the inhibition of protein expression by utilizing ... RNA (mRNA). Attempts to induce RNA interference ...
... is used to distinguish collagen from muscle ... System. The Trichrome stain is often used ... and to identify an increase in collagenous ... muscle is stained red, collagen - blue, ...
Biology Products: